AbbVie bets $48M upfront for early-stage antibody targeting chronic inflammation
AbbVie is making good on its plans to search for new mechanisms of action, this time with French biotech OSE Immunotherapeutics for a monoclonal antibody …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
